Investors

Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures in both the hospital and home settings.

NASDAQ: MRNS
$ 7.86 -0.78 (9.03%)
Day High: 8.80
Day Low:  7.66
Volume:    4,045,517
4:00 PM ET
Dec 8, 2017

Delayed ~20 min., by eSignal.